C12N 2310/52
Branched
Official title: branched
C12N2310/52 (Branched) appears on 72 US grants and 143 published applications in this corpus.
Search patents in C12N- Granted patents
- 72
- Published applications
- 143
- Assignees
- 59
- Inventors
- 226
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 3 |
| 2006 | 0 | 1 |
| 2007 | 1 | 3 |
| 2008 | 0 | 7 |
| 2009 | 0 | 1 |
| 2010 | 3 | 6 |
| 2011 | 1 | 2 |
| 2012 | 3 | 6 |
| 2013 | 3 | 1 |
| 2014 | 2 | 4 |
| 2015 | 6 | 11 |
| 2016 | 1 | 6 |
| 2017 | 9 | 9 |
| 2018 | 5 | 11 |
| 2019 | 7 | 12 |
| 2020 | 8 | 6 |
| 2021 | 3 | 13 |
| 2022 | 6 | 5 |
| 2023 | 3 | 9 |
| 2024 | 7 | 14 |
| 2025 | 1 | 5 |
| 2026 | 1 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Modulation of transthyretin expression21 Apr 2026US 12,606,826 B2Ionis Pharmaceuticals, Inc.
- O-methyl rich fully stabilized oligonucleotides13 May 2025US 12,297,430 B2University of Massachusetts
- RNA silencing nanozymes15 Oct 2024US 12,116,603 B2University of Florida Research Foundation, Inc.
- Oligonucleotides for SARS-CoV-2 modulation3 Sep 2024US 12,077,758 B2University of Massachusetts
- Meta-stable oligonucleotides junctions for delivery of therapeutics6 Aug 2024US 12,054,711 B2California Institute of Technology
- Oligonucleotides for htt-1a modulation10 Sep 2026US 2026/0265747 A1University of Massachusetts
- Oligonucleotides for mapt modulation23 Apr 2026US 2026/0109982 A1University of Massachusetts
- Compositions and methods for treatment of neurological disorders9 Apr 2026US 2026/0098264 A1Atalanta Therapeutics, Inc.
- Compositions and methods for treatment of spinocerebellar ataxias9 Apr 2026US 2026/0098265 A1Atalanta Therapeutics, Inc.
- Compositions and methods for treatment of neuroinflammatory diseases9 Apr 2026US 2026/0098269 A1Atalanta Therapeutics, Inc.
Most cited
By later US patents
- Antisense modulation of CD40 expression173US 7,745,609 B2Isis Pharmaceuticals, Inc. · 2010
- Chimeric immunomodulatory compounds and methods of using the same—I52US 7,255,868 B2Dynavax Technologies Corporation · 2007
- Oligonucleotide compounds for targeting huntingtin mRNA33US 9,809,817 B2University of Massachusetts · 2017
- Branched oligonucleotides as pathogen-inhibitory agents30US 6,489,464 B1Hybridon, Inc. · 2002
- Chimeric immunomodulatory compounds and methods of using the same24US 8,003,115 B2Dynavax Technologies Corporation · 2011